Replies to post #2143 on Iterum Therapeutics (ITRM)

[velcro]

You may be right.
"If the resubmission addresses all deficiencies in the complete response letter received in July 2021 from the FDA, then the FDA’s review and action will occur six months from receipt of the resubmission...."
"Iterum has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications including uUTI."
One of the Big Pharma companies could make a contingency partnership, but wondering why it takes so long to recruit patients?
If successful ka-ching, ka-ching in late 2024.